---
title: 'ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR'
description: >-
  Read the latest news on regulatory-grade real-world evidence: ACG 2024
  Research: Presentation by A. Sidney Barritt IV, MD, MSCR.
date: '2024-12-04'
category: News
tags:
  - Conference Presentation
  - R&D
  - Care
  - Cross-cutting
  - General
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/conference-presentation/acg-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: acg-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr
id: 4cY7MopTpXl5inTzAhco1p
contentType: article
---

Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study at ACG 2024 titled, *“Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality.”*

This video presentation explores the real-world impact of sodium-glucose cotransporter-2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors on patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Using data from the TARGET-NASH cohort, we investigate the association between these medications and key patient outcomes, including mortality and disease progression. Watch Dr. Barritt’s presentation of our latest insights.